A phase II study of dupilumab as an adjunctive therapy to immunotherapies for the treatment of grass allergy.

Trial Profile

A phase II study of dupilumab as an adjunctive therapy to immunotherapies for the treatment of grass allergy.

Planning
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2017

At a glance

  • Drugs Dupilumab (Primary)
  • Indications Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2017 New trial record
    • 13 Dec 2017 According to a Regeneron pharmaceutical media release, this study is planned to initiate in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top